{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:25:48Z","timestamp":1787955948721,"version":"build-2784847793"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>Alopecia areata (AA) is primarily associated with a Type 1 (Th1) inflammatory response, but emerging evidence also suggests a potential contribution of Type 2 (Th2) immunity. However, the relationship between IgE levels and pathogenesis of AA, as well as its clinical features, remains unclear, with limited and conflicting evidence in current research. This study aims to compare the total serum IgE levels between AA patients without atopic diseases and healthy controls, and to examine the correlation of IgE levels with gender, age, disease severity, disease duration, and affection of eyebrows, eyelashes, and nails.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AA patients without other hair loss diseases and conditions, or systemic treatment known to affect serum IgE were included. Medical records of 436 patients and 181 normal controls were retrospectively analyzed between May 2018 and November 2024. Among AA patients, clinical features and total serum IgE levels were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The elevated total serum IgE rate was observed in 31.0% of AA patients, which was significantly higher than that in control groups (P &amp;lt; 0.001). Among AA patients, total serum IgE levels differed significantly by gender (P = 0.002), age (P &amp;lt; 0.001), and disease severity (P = 0.040). Patients with alopecia universalis or totalis (AU\/AT) had higher total serum IgE levels compared to those with localized AA (P = 0.049). No significant correlation was found between total serum IgE levels and disease duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our research reveal that total serum IgE levels are elevated in AA patients compared to control group. Male patients, children, and individuals with moderate-severe AA patients showed significantly higher IgE levels. These results suggest the involvement of IgE and Th2 cytokines in AA pathogenesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1581976","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:22:25Z","timestamp":1748841745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation between increased total serum IgE levels and clinical features in alopecia areata patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Yijie","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103339","article-title":"Biomarkers in alopecia Areata: A systematic review and meta-analysis","volume":"22","author":"Zaaroura","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.031","article-title":"History of atopy or autoimmunity increases the risk of alopecia areata","volume":"61","author":"Barahmani","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12471","article-title":"Allergy to dust mites may contribute to the early onset and severity of alopecia areata","volume":"40","author":"Li","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00403-024-03225-4","article-title":"Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study","volume":"316","author":"David","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2312245","article-title":"Dupliumab therapy for alopecia areata: a case series and review of the literature","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatol Treat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517832","article-title":"Remission of alopecia universalis after 1 year of treatment with dupilumab in a patient with severe atopic dermatitis","volume":"8","author":"Romagnuolo","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/all.15561","article-title":"Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata","volume":"78","author":"Renert-Yuval","year":"2023","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for treating severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001929","article-title":"Lesson to learn from cellular infiltration in scalp biopsy of alopecia areata","volume":"43","author":"Genedy","year":"2021","journal-title":"Am J Dermatopathology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138099","article-title":"IgE-Fc\u03f5RI protein-protein interaction as a therapeutic target against allergic asthma: An updated review","volume":"284","author":"Liu","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IGE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00884-x","article-title":"Predictors and management of inadequate response to JAK inhibitors in alopecia areata","volume":"25","author":"Zhang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00689","article-title":"Immunoglobulin E-mediated autoimmunity","volume":"9","author":"Maurer","year":"2018","journal-title":"Front Immunol"},{"key":"B18","first-page":"77","article-title":"Total IgE levels in the serum in dermatologic diseases","volume":"37","author":"Przybilla","year":"1986","journal-title":"Hautarzt"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640030055008","article-title":"Serum IgE in dermatitis and dermatosis: an analysis of 497 cases","volume":"113","author":"O\u2019Loughlin","year":"1977","journal-title":"Arch Dermatol"},{"key":"B20","article-title":"Serum levels of total immunoglobulin e in patients with alopecia areata: relationship with the clinical type of the disease","volume":"14","author":"Kasumagi\u0107-Halilovi\u0107","year":"2006","journal-title":"Acta Dermatovenerol Croat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/503587","article-title":"Serum interleukin-4 and total immunoglobulin E in nonatopic alopecia areata patients and HLA-DRB1 typing","volume":"2010","author":"Attia","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.131076","article-title":"Total serum immunoglobulin E in patients with alopecia areata","volume":"5","author":"Bakry","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12865-022-00486-4","article-title":"CD4, CD8 and natural killer cells are depressed in patients with alopecia areata: their association with disease activity","volume":"23","author":"Younes","year":"2022","journal-title":"BMC Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.02.080","article-title":"Activated regulatory T cells are increased in patients with alopecia areata for suppressing disease acitivity","volume":"86","author":"Kubo","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0210308","DOI":"10.1371\/journal.pone.0210308","article-title":"Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCR\u03b2-chain, which highlights the immunopathological aspect of the disease","volume":"14","author":"Hamed","year":"2019","journal-title":"Ria F Ed PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/839684","article-title":"Chemokine receptor expression on normal blood CD56+ NK-cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK-cell population","volume":"2015","author":"Lima","year":"2015","journal-title":"J Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0301-x","article-title":"Heterogeneity in the initiation, development and function of type 2 immunity","volume":"20","author":"Gause","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14541","article-title":"Estimation of CD3, CD4, and CD8 in Iraqi patients with alopecia areata and alopecia universalis","volume":"21","author":"Aldaffaie","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.032","article-title":"Alopecia universalis associated with impaired interleukin-4 production and low serum IgE level","volume":"57","author":"Tokura","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a270","article-title":"Dupilumab and alopecia areata: A possible combined or disturbance therapy? A review of the literature","volume":"14","author":"Starace","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","article-title":"British Association of Dermatologists living guideline for managing people with alopecia areata 2024","volume":"192","author":"Harries","year":"2025","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.010","article-title":"Cause or cure? Review of dupilumab and alopecia areata","volume":"88","author":"Marks","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1581976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:22:25Z","timestamp":1748841745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1581976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1581976"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1581976","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"article-number":"1581976"}}